U.S. imports of gastrointestinal disease drugs, PPIs, climbed 10% in the third quarter, driven by a 45% jump in September of generic Nexium imports. The growth in imports for the class has been much slower than for anticonvulsants (37% higher in the quarter) and statins (21%). This reflects the more mature nature of the drugs and a lack of recent new uses. Investigations into links to kidney disorders may cut imports in the longer term.